Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACOG Alpha Cognition	$9.40 -6.8%	$6.22	$3.75 ▼ $11.40	$161.64M	2.48	102,027 shs	122,876 shs
ACRV Acrivon Therapeutics	$1.10	$1.52	$1.05 ▼ $10.16	$34.49M	1.88	235,010 shs	621,166 shs
EPRX Eupraxia Pharmaceuticals	$3.93	$3.59	$2.20 ▼ $4.48	$140.89M	N/A	13,100 shs	7,576 shs
TIL Instil Bio	$26.08 -14.1%	$16.54	$9.62 ▼ $92.00	$171.06M	1.78	154,561 shs	811,034 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACOG Alpha Cognition	-6.84%	+2.84%	+70.29%	+56.41%	+939,999,900.00%
ACRV Acrivon Therapeutics	0.00%	-5.98%	-21.43%	-79.28%	-85.33%
EPRX Eupraxia Pharmaceuticals	0.00%	+1.55%	-4.15%	-1.13%	+41.37%
TIL Instil Bio	-14.07%	+24.07%	+102.96%	+29.75%	+146.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACOG Alpha Cognition	1.6485 of 5 stars	3.5	0.0	2.7	0.8	0.0
ACRV Acrivon Therapeutics	3.6741 of 5 stars	4.5	3.0	2.2	3.3	0.6
EPRX Eupraxia Pharmaceuticals	2.1646 of 5 stars	3.7	1.0	2.5	0.0	0.6
TIL Instil Bio	3.4011 of 5 stars	3.5	4.0	1.7	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACOG Alpha Cognition	3.00	Buy	$20.00	112.77% Upside
ACRV Acrivon Therapeutics	3.00	Buy	$17.71	1,510.39% Upside
EPRX Eupraxia Pharmaceuticals	3.33	Buy	$10.50	167.18% Upside
TIL Instil Bio	3.00	Buy	$112.33	330.73% Upside

Current Analyst Ratings Breakdown

Latest ACRV, ACOG, EPRX, and TIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/22/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$110.00 ➝ $105.00
5/16/2025	ACOG Alpha Cognition	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/16/2025	ACRV Acrivon Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/15/2025	ACRV Acrivon Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/5/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
5/4/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/31/2025	ACOG Alpha Cognition	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/26/2025	ACRV Acrivon Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/26/2025	ACRV Acrivon Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $19.00
3/25/2025	ACOG Alpha Cognition	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy
3/18/2025	ACOG Alpha Cognition	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00

(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACOG Alpha Cognition	$2.93M	51.42	N/A	N/A	($1.08) per share	-8.70
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$5.38 per share	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	$0.03 per share	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	$34.72 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACOG Alpha Cognition	-$13.77M	-$1.20	N/A	∞	N/A	N/A	N/A	-344.17%	8/11/2025 (Estimated)
ACRV Acrivon Therapeutics	-$60.39M	-$2.22	N/A	N/A	N/A	N/A	-47.95%	-43.73%	8/12/2025 (Estimated)
EPRX Eupraxia Pharmaceuticals	-$28.22M	-$0.76	N/A	N/A	N/A	N/A	-219.64%	-96.00%	8/6/2025 (Estimated)
TIL Instil Bio	-$156.09M	-$11.97	N/A	N/A	N/A	N/A	-37.44%	-25.08%	8/12/2025 (Estimated)

Latest ACRV, ACOG, EPRX, and TIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ACOG Alpha Cognition	-$0.58	-$0.20	+$0.38	-$0.13	$0.50 million	$2.93 million
5/13/2025	Q1 2025	ACRV Acrivon Therapeutics	-$0.57	-$0.51	+$0.06	-$0.51	N/A	N/A
5/13/2025	Q1 2025	TIL Instil Bio	-$2.02	-$4.32	-$2.30	-$4.32	N/A	N/A
5/6/2025	Q1 2025	EPRX Eupraxia Pharmaceuticals	-$0.19	-$0.21	-$0.02	-$0.21	N/A	N/A
3/31/2025	Q4 2024	ACOG Alpha Cognition	-$0.48	-$0.51	-$0.03	-$0.51	N/A	N/A
3/27/2025	Q4 2024	ACRV Acrivon Therapeutics	-$0.69	-$0.60	+$0.09	-$0.60	N/A	N/A
3/20/2025	Q4 2024	EPRX Eupraxia Pharmaceuticals	-$0.20	-$0.21	-$0.01	-$0.21	N/A	N/A
3/4/2025	Q4 2024	TIL Instil Bio	-$3.75	-$1.82	+$1.93	-$1.82	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACOG Alpha Cognition	N/A	N/A	N/A	N/A	N/A
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACOG Alpha Cognition	N/A	1.50	1.50
ACRV Acrivon Therapeutics	N/A	12.75	12.75
EPRX Eupraxia Pharmaceuticals	N/A	4.17	4.17
TIL Instil Bio	0.47	12.90	12.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACOG Alpha Cognition	N/A
ACRV Acrivon Therapeutics	71.62%
EPRX Eupraxia Pharmaceuticals	N/A
TIL Instil Bio	60.56%

Insider Ownership

Company	Insider Ownership
ACOG Alpha Cognition	14.00%
ACRV Acrivon Therapeutics	11.90%
EPRX Eupraxia Pharmaceuticals	N/A
TIL Instil Bio	46.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACOG Alpha Cognition	N/A	16.02 million	10.97 million	N/A
ACRV Acrivon Therapeutics	58	31.36 million	28.49 million	Not Optionable
EPRX Eupraxia Pharmaceuticals	29	35.85 million	N/A	N/A
TIL Instil Bio	410	6.56 million	3.49 million	No Data

ACRV, ACOG, EPRX, and TIL Headlines

Recent News About These Companies

Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference

May 30 at 7:00 AM | globenewswire.com

Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?

May 29 at 1:06 PM | zacks.com

Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade

May 29 at 11:00 AM | zacks.com

Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success

May 25, 2025 | seekingalpha.com

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ...

May 25, 2025 | morningstar.com

Instil Bio stock price target cut to $105 by H.C. Wainwright

May 24, 2025 | uk.investing.com

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in ...

May 24, 2025 | seekingalpha.com

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

May 23, 2025 | globenewswire.com

Instil Bio Shares Jump on Trial Updates for Lung Cancer Treatment

May 23, 2025 | marketwatch.com

Instil Bio shares rise on immunotherapy trial updates

May 23, 2025 | msn.com

Instil Bio shares rise after updates on cancer trials

May 23, 2025 | seekingalpha.com

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025

May 22, 2025 | globenewswire.com

Instil Bio, Inc. Progresses with Ongoing NSCLC Trials for AXN-2510/IMM2510 and Reports Q1 2025 Financial Results

May 13, 2025 | quiverquant.com

Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025 | globenewswire.com

Instil Bio reports Q4 adjusted EPS ($1.08) vs. ($1.26) last year

March 4, 2025 | markets.businessinsider.com

Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 4, 2025 | globenewswire.com

Instil Bio: Time To Hop On The Summit Wave?

February 24, 2025 | seekingalpha.com

Private equity firms who hold 38% of Instil Bio, Inc. (NASDAQ:TIL) gained 34%, institutions profited as well

February 20, 2025 | finance.yahoo.com

JMP Securities Keeps Their Hold Rating on Instil Bio (TIL)

February 13, 2025 | markets.businessinsider.com

Summit Therapeutics (NASDAQ:SMMT) Stock Quotes, Forecast and News Summary

January 24, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV, ACOG, EPRX, and TIL Company Descriptions

Alpha Cognition NASDAQ:ACOG

$9.40 -0.69 (-6.84%)

As of 05/30/2025 04:00 PM Eastern

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Acrivon Therapeutics NASDAQ:ACRV

$1.10 0.00 (0.00%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.06 -0.04 (-3.18%)

As of 05/30/2025 07:59 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Eupraxia Pharmaceuticals NASDAQ:EPRX

$3.93 0.00 (0.00%)

Closing price 05/30/2025 03:59 PM Eastern

Extended Trading

$3.89 -0.04 (-1.02%)

As of 05/30/2025 05:26 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Instil Bio NASDAQ:TIL

$26.08 -4.27 (-14.07%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$26.80 +0.72 (+2.76%)

As of 05/30/2025 07:30 PM Eastern

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time